FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Interesting Engineering on MSN4 天
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
The Pharma Letter6 天
FDA nod for first rapid-acting insulin biosimilar
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...
Managed Healthcare Executive3 天
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Daily5 天
Sanofi's Merilog Receives USFDA Approval as Biosimilar to Novolog for Diabetes Management
Sanofi has received U.S. Food and Drug Administration (FDA) approval for Merilog (insulin-aspart-szjj), a biosimilar to ...
来自MSN6 天
FDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for ...
The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...
KTEN4 天
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog is a rapid-acting human insulin analog and the first rapid-acting ... Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval.